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ABSTRACT
Objective Precision oncology depends on translating 
molecular data into therapy recommendations. However, 
with the growing complexity of next- generation 
sequencing- based tests, clinical interpretation of somatic 
genomic mutations has evolved into a formidable task. 
Here, we compared the performance of three commercial 
clinical decision support tools, that is, NAVIFY Mutation 
Profiler (NAVIFY; Roche), QIAGEN Clinical Insight (QCI) 
Interpret (QIAGEN) and CureMatch Bionov (CureMatch).
Methods In order to obtain the current status of the 
respective tumour genome, we analysed cell- free DNA 
from patients with metastatic breast, colorectal or 
non- small cell lung cancer. We evaluated somatic copy 
number alterations and in parallel applied a 77- gene panel 
(AVENIO ctDNA Expanded Panel). We then assessed the 
concordance of tier classification approaches between 
NAVIFY and QCI and compared the strategies to determine 
actionability among all three platforms. Finally, we 
quantified the alignment of treatment suggestions across 
all decision tools.
Results Each platform varied in its mode of variant 
classification and strategy for identifying druggable targets 
and clinical trials, which resulted in major discrepancies. 
Even the frequency of concordant actionable events for 
tier I- A or tier I- B classifications was only 4.3%, 9.5% and 
28.4% when comparing NAVIFY with QCI, NAVIFY with 
CureMatch and CureMatch with QCI, respectively, and the 
obtained treatment recommendations differed drastically.
Conclusions Treatment decisions based on molecular 
markers appear at present to be arbitrary and dependent 
on the chosen strategy. As a consequence, tumours with 
identical molecular profiles would be differently treated, 
which challenges the promising concepts of genome- 
informed medicine.
INTRODUCTION
Based on the concept that somatic muta-
tions are the foundation of cancer develop-
ment,1 2 genomics is leading the development 
in precision oncology. However, the imple-
mentation of precision oncology is complex 
and involves a cascade of various individual 
steps (figure 1A). Beginning with informed 
consent and, if applicable, genetic counsel-
ling, tissue or blood is subjected to clinical- 
grade sequencing. Bioinformatics analyses 
enable the quantification of tumour allele 
fraction (AF), detection of somatic copy 
number alterations (SCNAs), single nucleo-
tide variants (SNVs), that is, point mutations, 
Key questions
What is already known about this subject?
 ► Precision oncology knowledge bases have become 
increasingly useful in annotating complex next- 
generation sequencing data for identifying drugga-
ble targets.
 ► Clinical interpretation of somatic genomic muta-
tions, however, remains a formidable task.
 ► Discrepant variant interpretation among open- 
source knowledge bases has led to recent harmon-
isation efforts.
What does this study add?
 ► This study represents an in- depth evaluation of three 
commercial clinical decision support tools, including 
a machine- learning platform which assigns person-
alised combination treatment recommendations.
 ► This is the first study employing clinical decision 
support analysis through comprehensive genom-
ic profiling of circulating tumour DNA, which rep-
resents a potential routine clinical application.
 ► Herein, detailed descriptions of discrepancies in 
pathogenicity, actionability and especially alignment 
of treatment matching are provided.
How might this impact on clinical practice?
 ► Our analyses demonstrate the complexity of treat-
ment matching algorithms and how variable algo-
rithms of decision support tools lead to discrepant 
outputs. As these interpreted reports are central to 
molecular tumour board discussions, the findings 
are pertinent to both oncologist and patient and may 
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and indels. Subsequently, the alterations must be inter-
preted for clinical relevance, ideally in the setting of an 
interdisciplinary molecular tumour board (MTB). The 
MTB faces the task of identifying druggable targets and 
disturbed pathways to match driver aberrations with 
existing drugs. Once a suitable treatment option has 
Figure 1 Steps involved in precision oncology and summary of molecular profiling data. (A) Cascade of individual steps 
involved in precision oncology: due to the increasingly extensive sequencing involved in precision oncology, genetic 
counselling may be required and an informed consent needs to be obtained in every case. Sequencing can be conducted 
with a tissue sample and/or from blood after isolation of plasma DNA, the latter being the specimen used in our study. 
Subsequently, various sequencing strategies can be applied to the sample to determine tumour AF and to detect alterations 
such as SNVs (point mutations) and indels, SCNAs and fusions. A decisive step in precision oncology is variant annotation, 
the molecular and clinical interpretation of targets and matching these with drugs. In this study, the data were subjected 
to interpretation by three clinical decision support tools (NAVIFY, QCI, CureMatch) to obtain treatment possibilities. The 
multidisciplinary MTB evaluates the data and gives advice to the treating physician. Afterwards, the results are disclosed to 
the patient and matched to their clinical status and, if applicable, the treatment is started. These last two steps were not within 
the scope of our retrospective study. (B) Oncoplots showing top 40 genes affected by mutation (ie, SNV or indel) and/or SCNA 
identified in plasma DNA for patients with BC (left), CRC (centre) and NSCLC (right). SCNAs are represented by either focal 
amplification (Amp) or focal deletion (Del). For patients with BC, hormone receptor status is shown as a clinical feature below 
the plot for each patient (ER, PR, HER2) as either positive (Pos) or negative (Neg). Similarly, if evaluated, PD- L1 expression 
status is shown as a clinical feature below the plot for patients with NSCLC as a per cent. AF, allele fraction; ER, oestrogen 
receptor; HER2, human epidermal growth factor receptor 2; ND, not detected; NSCLC, non- small- cell lung cancer; PR, 
















pen: first published as 10.1136/esm







3Perakis SO, et al. ESMO Open 2020;5:e000872. doi:10.1136/esmoopen-2020-000872 Perakis SO, et al. ESMO Open 2020;5:e000872. doi:10.1136/esmoopen-2020-000872
been identified, it is aligned with the clinical status and 
disclosed to the patient (figure 1A).
However, annotation and interpretation of gene vari-
ants in terms of their tumourigenicity and drug action-
ability is a daunting task. Hence, to support clinicians 
and MTBs, there is a growing number of resources for 
data curation, both commercial tools or open- source 
platforms, such as OncoKB,3 My Cancer Genome,4 Preci-
sion Medicine Knowledge Base (PMKB),5 Personalised 
Cancer Therapy,6 Clinical Interpretation of Variants in 
Cancer (CIViC),7 Jackson Laboratory Clinical Knowl-
edge base (JAX- CKB),8 Cancer Genome Interpreter 
Cancer Biomarkers Database (CGI),9 Cancer Driver Log 
(omicX),10 N- of- One (https:// n- of- one. com/; QIAGEN), 
Watson for Genomics (WfG)11 and MolecularMatch 
(MMatch) ( www. molecularmatch. com). However, little 
is known about the actual performances of these plat-
forms. Initial comparisons in respect to their annotations 
for pathogenicity and actionability of three (NoO, WfG, 
and OncoKB)12 or six (CGI, CIViC, JAX- CKB, MMatch, 
OncoKB, PMKB)13 of these platforms each found that 
these were very disparate in content, resulting in dramatic 
differences in variant interpretation.
Given the urgency to evaluate the performance of clin-
ical decision tools, here we evaluated three commercial 
packages, that is, NAVIFY Mutation Profiler (Roche), 
QIAGEN Clinical Insight (QCI) Interpret (QIAGEN) 
and CureMatch Bionov (CureMatch). Each of the 
three platforms exhibits inherent differences in their 
strategies, ranging from data input format, to variant 
classification, to treatment matching (details in online 
supplemental data) as well as product costs. In order to 
test these platforms under conditions as they actually 
occur in routine clinical practice, we assessed cell- free 
DNA (cfDNA), which in patients with cancer contains 
circulating tumour DNA (ctDNA), as an innovative 
approach to generate comprehensive profiles of the 
respective tumour genomes. ctDNA offers an accurate 
snapshot of the tumour’s most current status14–16 and 
can effectively detect alterations present concurrently 
in distinct tumour subclones and different metastatic 
lesions.17 18 Furthermore, initial studies are already using 
ctDNA to guide a subset of patients to specific therapies 
in clinical trials.19
The main objectives of our study were threefold: 
first, from the three platforms, only NAVIFY and QCI 
employed tier classification approaches (details below 
and in online supplemental data) and therefore we 
evaluated the concordance of tier classification between 
these two platforms. Second, we compared philoso-
phies of actionability among all three platforms. Third, 
we quantified the alignment of treatment suggestions 
across all decision tools. Our study illustrates the urgent 
need for standardisation of annotation, interpretation 
and treatment matching algorithms prior to clinical 
implementation.
RESULTS
Patient cohorts and molecular profiling from plasma DNA
In total, we analysed 48 plasma samples with relatively 
high ctDNA from patients with advanced stage breast 
cancer (BC, n=12), colorectal cancer (CRC, n=17) and 
non- small- cell lung cancer (NSCLC, n=19). Median age 
of the total patient cohort was 61 years (range 48–79) 
and patients had received a median of 2.5 prior lines of 
therapy (see online supplemental table S1). All plasma 
samples were analysed with a 77- gene panel (AVENIO 
ctDNA Expanded Panel; online supplemental table 
S2) and by plasma- Seq20 to map SCNAs including focal 
events according to our previous definition21 and to 
quantify tumour fraction (TF) with ichorCNA.22 Median 
ichorCNA- derived TFs were 24.95% (range 10.52–48.93), 
14.94% (range 4.07–54.69) and 4.46% (range 1.63–45.42) 
in patients with BC, CRC and NSCLC, respectively (see 
online supplemental figure S1). As expected, the most 
frequent mutations were consistent with published tissue- 
derived data for the respective tumour entity. For each 
patient, we then generated a list of markers including focal 
SCNAs, non- synonymous SNVs, indels, potential splice 
variants and, if applicable, immunohistochemistry (IHC) 
markers such as PD- L1- staining for NSCLC or hormone 
receptor/Her2 status for BC (figure 1B). Patients with 
BC had the highest number of markers due to the high 
number of focal SCNAs in plasma and available hormone 
receptor status, followed by CRC and NSCLC (see online 
supplemental figure S1).
Clinical decision support tools vary across features and 
strategies
Each of the three platforms described here has distinct 
differences (table 1; online supplemental tables S3–S4). 
In brief (details in online supplemental data), NAVIFY 
employs the most stringent classification of somatic variants 
in accordance with Association for Molecular Pathology 
(AMP) guidelines23 and deems only well- established tier 
I- A, I- B and II- C alterations as actionable. QCI Interpret 
uses American College of Medical Genetics and Genomics 
(ACMG) guidelines24 to determine pathogenicity and 
AMP guidelines to determine actionability and does not 
prioritise the alterations or treatment recommendations, 
thus leaving such decisions to the individual generating 
the report or to the clinician receiving it. Both NAVIFY 
and QCI report functional as well as predicted biochem-
ical impact (eg, Combined Annotation- Dependent 
Depletion (CADD),25 PolyPhen (Polymorphism Pheno-
typing; http:// genetics. bwh. harvard. edu/ pph2/)) and 
QCI furthermore provides laboratory observations, effect 
on protein, prognostic outcomes, somatic frequency, as 
well as an interactive genome browser. Since the QCI plat-
form requires manual curation of information by the end 
user, these additional supporting visual aids, especially 
the detailed explanation of the computed classifications, 
reported functional impact and effect on protein, aid the 
interpretation workflow and accordingly influence the 
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The CureMatch strategy differs greatly as it involves the 
ranking and prioritisation of alterations and treatments 
for implementation of combination therapy, targeting 
the entire aberrant profile rather than simply matching 
treatments to individual targets. Therapy recommen-
dations are accompanied by a proprietary ‘Matching 
Score’ (Boichard et al26 see details in Methods section), 
which prioritises therapies and generates the top three 
3- drug and 2- drug combination therapies and top three 
monotherapies. Furthermore, it is possible to incor-
porate patient- specific history, such as prior treatment 
lines, comorbidities and medical history, into CureMatch 
analyses.
NAVIFY and QCI generated different tier-based classifications
Both NAVIFY (V.1.1.0.3d9a34b, release date: 26 August 
2019) and QCI (V.5.5.20190701) analyses were performed 
with identical datasets (VCFs, variant call files) and, as both 
of these tools apply a tier- based somatic variant classification, 
we started with a detailed comparison between the two (soft-
ware details in online supplemental data). Because NAVIFY 
also considers pertinent negative genes in its analysis, that is, 
KRAS/NRAS wild- type status is designated tier I- A in CRC, as 
well as potentially relevant coalterations, for example, co- oc-
currence of a KRAS mutation and MET amplification in CRC, 
NAVIFY yielded a higher total number of classifications (551 
Table 1 Summary of decision support tool features
Roche NAVIFY Mutation 
Profiler QIAGEN QCI Interpret CureMatch Bionov
Platform Web application Web application A HIPAA and GDPR compliant web- 
based application available to users
Data input format VCF VCF Annotated patient report (PDF)
Considers clinical 
characteristics such as prior 
treatment lines, comorbidities, 
medical history
No No Yes (if provided by the user)
Analysis of SCNAs Yes, manual entry (segment 
information optional)
Yes, manual entry Yes
Variant filtration VCF filtered on user- defined 
assay parameters
VCF filtered on user- defined 
assay parameters
Filtration done in lab prior to 
submission
Variant classification AMP guidelines Mixed ACMG/AMP guidelines Lab- specific guidelines for 
annotating variants and determining 
pathogenicity
Inclusions of VUSs in report Yes Yes, but not by default Yes




Yes, only tumour- specific 
recommendations for 
established tier I variants
Yes, only tumour- specific 
recommendations for 
established tier I variants
Yes
Suggestion of clinical trials Yes, can adjust for location Yes, shows currently enrolling 
studies involving variant
Provides clinical trial information 
as evidence for the recommended 
combinations
Variables considered for clinical 
trial matching
Age, sex, user- defined 
location, tumour type, 
molecular alteration, treatment
User- defined location, tumour 
type, molecular alteration, 
treatment
  
Off- label suggestions Yes Yes, but not by default Yes
Report reviewed by external 
clinical team
No No Yes
Virtual molecular tumour board 
option
Only in combination with other 
NAVIFY products in portfolio 
(NAVIFY Tumor Board)
No Yes
Estimated time to generate 
report*
30–45 minutes† 30–60 minutes† 48–72 hours‡
*Estimation is based on our experience only with the data used in this study. Time for report generation varies for each case and is 
dependent on user experience, the number of aberrations reported and the end user’s analysis strategy.
†Includes data upload and hands- on time.
‡Vendor estimate of turnaround time for report generation (analysis performed by vendor).
ACMG, American College of Medical Genetics and Genomics; AMP, Association for Molecular Pathology; GDPR, General Data 
Protection Regulation; HIPAA, Health Insurance Portability and Accountability Act; QCI, QIAGEN Clinical Insight; SCNAs, somatic copy 
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total classifications) compared with all combined QCI anal-
yses (492 total classifications, see online supplemental figure 
S2).
Altogether, we considered 492 alterations that over-
lapped between both platforms. From these 492 alter-
ations, 344 (70%) were concordant and 148 (30%) 
comprised discordant events. We were particularly inter-
ested in tier I classifications. Across all 48 patients, 14 
(4.1%) alterations were classified concordantly as tier I- A 
between NAVIFY and QCI, with only QCI demonstrating 
47 discordant and unique I- A designations (figure 2A, 
online supplemental figure S3A). Similarly, there were 
only eight alterations (2.3%) classified concordantly as I- B 
by both platforms (figure 2A, online supplemental figure 
S3A). Not surprisingly, all of these tier I concordantly 
classified alterations consisted of established predictive 
somatic alterations, such as the V600E BRAF or the G12 
and Q61 KRAS variants or amplifications of ERBB2 or 
MET (see online supplemental table S5). Tier III variant 
of unknown significance designations comprised the 
majority of concordance between platforms, followed by 
II- C and with the least overlap among II- D designations 
(figure 2B). An aberration type- based analysis revealed 
that the majority of concordant events came from SNVs 
and amplifications, that is 43.9% and 52.6%, respectively 
(see online supplemental figure S3A).
Of the total 148 discordant events, 63 alterations (43%) 
involved tier I alterations. Forty- seven (32%) were classi-
fied as tier I- A by one platform (QCI) but differently by 
the other (NAVIFY), that is, 15 (10%) as tier I- B and 32 
alterations (22%) as tier II- C or tier II- D, indicating that 
classification of a variant as actionable by one platform 
but not by another is a frequent event (see online supple-
mental figure S3B).
All platforms demonstrated differences in determination of 
actionability
We compared side- by- side actionability for each variant 
across the three platforms, including the designated 
tier classifications for NAVIFY and QCI, by labelling 
the alteration as either actionable or not depending on 
each software’s output. We first compared NAVIFY and 
QCI and observed that only 4.3% (21/492 alterations) 
of events were classified as actionable by both platforms, 
which included ERBB2 and MET amplifications, PIK3CA 
Figure 2 Concordant and discordant classifications of aberrations using NAVIFY and QCI. (A) Venn diagrams displaying 
the number of concordant and discordant tier I- A (top) and tier I- B (bottom) classifications as annotated by NAVIFY and QCI 
across all 48 patients. (B) Venn diagrams displaying the number of concordant and discordant tier II- C (top) and tier II- D 
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mutations and one case of a RABGAP1L–ROS1 fusion 
(see online supplemental table S6). Discrepancies in 
actionability originated from diverse SCNAs and muta-
tions and included well- established predictive markers. 
For example, NAVIFY identified MET amplifications 
as actionable whereas QCI did not (see online supple-
mental table S6). The latter suggests the importance of 
the context of tumour type for certain platforms, as QCI 
only called MET amplifications in the NSCLC setting to 
be druggable, whereas NAVIFY listed this as an off- label 
indication outside of the NSCLC context. Similarly, QCI 
deemed activating mutations in KRAS, NRAS or EGFR 
amplification actionable, whereas NAVIFY did not.
We then compared concordance of actionability per 
target for the 492 NAVIFY/QCI alterations with Cure-
Match and observed a 66.3% (326/492 alterations) and 
80.1% (394/492) concordance with NAVIFY and QCI, 
respectively. Again, the number of concordant events 
between two platforms which were actually targetable 
was minor, that is, 9.5% (31/326) between NAVIFY and 
CureMatch and 28.4% (112/394) between QCI and 
CureMatch (see online supplemental tables S7 and S8). 
Higher targetabilities between QCI and CureMatch 
compared with NAVIFY is a result of the QCI algorithm, 
which also recommends suitable cytotoxic regimens for 
an aberration, although this drug may not be a direct 
‘match’, that is, targeted agent, whereas NAVIFY only lists 
chemotherapy possibilities in conjunction with a targeted 
agent.
We then compared the total number of submitted 
markers, actionable targets and matching drugs per 
patient and tumour entity (figure 3A–C). For patients 
with targetable aberrations, there was a statistically signif-
icant association with the number of therapies for all 
three platforms (NAVIFY: figure 3A, online supplemental 
figure S4A, Pearson’s R=0.743, p=0.02; QCI: figure 3B, 
online supplemental figure S4B, Pearson’s R=0.493, 
p=0.003; CureMatch: figure 3C, online supplemental 
figure S4C, Pearson’s R=0.766, p<0.001). Furthermore, 
CureMatch identified a correlation between the number 
of actionable targets with the number of focal SCNAs 
detected (Pearson’s correlation coefficient R=0.524, 
p<0.001, see online supplemental figure S3C). For both 
CureMatch and QCI, patients with CRC had the highest 
median number of actionable targets and all platforms 
identified the highest median number of matching drugs 
for patients with CRC (figure 3A–C). Interestingly, with 
CureMatch, actionability of alterations varied within the 
Figure 3 Reported markers, actionability and number of treatment suggestions. (A–C) Stacked bar charts from NAVIFY 
(A: top), QCI (B: centre) and CureMatch (C: bottom) per patient and per tumour entity (left, BC; centre, CRC; right, NSCLC). 
Reported markers (orange) represent all alterations reported to the clinical decision support tool, whereas actionable targets 
(turquoise) are those alterations which were successfully matched to a therapy. Matching drugs (dark blue) correspond to the 
total number of drugs identified for each patient's molecular profile. In the CureMatch analysis, the actionable targets in the 
BC and NSCLC samples could be categorised as either a genome (light blue) or protein variant (red). BC, breast cancer; CRC, 
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same gene and/or domain, indicating dependency of 
targetability on the specific somatic variant reported in 
patients with CRC (see online supplemental figure S4D) 
and NSCLC (see online supplemental figure S4E).
To assess variation in actionability interpretation, we 
calculated the average per cent actionability defined 
by each tool by dividing the total number of actionable 
targets by the total number of submitted markers. Median 
overall actionability was highest with CureMatch in all 
cohorts (see online supplemental figure S5), whereas due 
to the stringent classification algorithm, patient genomes 
had the lowest median per cent actionability with NAVIFY.
Treatment options were identified for the majority of patients 
but varied across all platforms
NAVIFY matched 29 (60%)/48 patients to an existing 
targeted therapy and was unable to match targeted 
treatments for 19 cases (40%, see online supplemental 
table S11) and the majority of the matches had an on 
compendia designation (figure 4A). QCI recommended 
treatments for 45 (94%)/48 patients, although these were, 
due to QCI’s different algorithm, not necessarily targeted 
agents (see online supplemental data, table S12). When 
all chemotherapeutic agents recommended by QCI (not 
including those recommended as a combination therapy 
with a targeted agent) are removed from the analysis on a 
per- patient basis, the number of drug recommendations 
per patient profile is reduced on average by 3.5, 4.6 and 
2.8 drugs for patients with BC, CRC and NSCLC, respec-
tively. For CureMatch analyses, at least one biomarker- 
guided therapy was identified, although 10 cases did not 
match a 3- drug combination and 2 cases only had mono-
therapy suggestions (see online supplemental table S9 
and figure 7B). The highest number of off- label and on 
compendia suggestions were made for patients with BC 
and NSCLC, respectively (figure 4A, online supplemental 
data).
We then assessed how often the recommendations 
align across all three platforms. We observed, rather 
surprisingly, very minimal alignment, with CureMatch 
and QCI aligning most frequently with a two- drug overlap 
Figure 4 Treatment suggestions per decision support platform. (A) Frequency of on compendia or off- label indications 
per tumour type for NAVIFY (left) and CureMatch (right). (B) Frequency of overlapping suggested therapies per platform 
comparison and per number of drugs. The platform recommendations were compared side- by- side with each other and all 
three together (x- axis). The number of drugs overlapping from the recommendations is listed on the y- axis. The numbers 
inside the boxes represent the number of events fitting each category. (C) Treatment alignment among all three platforms 
was limited to common predictive biomarkers. Here, the most frequently overlapping drugs are shown along with how each 
decision support platform justified the drug, which sometimes varied. BC, breast cancer; CM, CureMatch; CRC, colorectal 
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(figure 4B). There were only seven instances in which 
all three platforms agreed on at least two drugs for the 
particular patient and of these cases, six were patients 
with CRC with cetuximab/panitumumab recommenda-
tions and one was a patient with BC harbouring a PIK3CA 
alteration matching to a fulvestrant and alpelisib combi-
nation (see online supplemental table S14). Other minor 
overlaps involved two cases of a 1- drug alignment of crizo-
tinib or fulvestrant or a 3- drug alignment of lapatinib, 
olaparib and talazoparib for ERBB2 or BRCA1 alterations 
or afatinib, dacomitinib or erlotinib for a single EGFR 
alteration (figure 4C). Another surprising finding was 
that for several cases in which treatment recommenda-
tions aligned among platforms, the actionable target justi-
fying the match varied (see online supplemental table 
S14). In fact, treatment alignment among all three plat-
forms was limited to a few common predictive biomarkers 
(figure 4C).
Decision support platforms identified a high number of 
clinical trials
For NAVIFY, location- specific clinical trials had a high 
degree of matching, with 8 (67%)/12, 16 (94%)/17 and 8 
(42%)/19 patients qualifying for a biomarker- based clinical 
trial in patients with BC, CRC and NSCLC, respectively, and 
with some patients with BC being eligible for more than 
seven trials (figure 5A, online supplemental figure S6). 
With QCI, roughly half of patients with BC (6/12; 50%) and 
NSCLC (9/19; 47%) and 15/17 (88%) of patients with CRC 
matched to existing trials in the user- defined location radius 
(figure 5A, online supplemental figure S6).
Additionally, we averaged the CureMatch top three 
highest and bottom three lowest matching scores for 
each of the regimens and observed the maximum median 
‘highest’ and ‘lowest’ matching score in patients with 
NSCLC (figure 5B, online supplemental figure S7A). 
These scores were summarised across each category to 
illustrate the distribution of ‘best fits’ per patient and 
several cases demonstrated similar matching scores 
regardless of treatment strategy (ie, combination or 
monotherapy, see online supplemental figure S7B). In 
terms of identifying clinical trials, the CureMatch algo-
rithm provides trial information as evidence for the 
recommended combinations. In this regard, more CRC 
cases matched to existing trials compared with BC and 
NSCLC, with 9 (53%)/17 patients of the cohort at least 
being attributed to one match (figure 5A).
DISCUSSION
Here we comprehensively profiled cfDNA from patients with 
common tumour entities, selecting cfDNA as an analyte and 
preferred tool for obtaining a current snapshot of tumour 
genome properties at any time during a disease course.14–16 19 
From the precision oncology cascade (figure 1A), we focused 
on a decisive step, that is, how to use information obtained 
from high- throughput sequencing to translate aberrations 
into appropriate therapies. Using three commercial tools, 
we observed that each platform has a different approach 
and strategy. As a consequence, each differs regarding 
variant annotation and, importantly, in deducing treatment 
recommendations. Our plasma analyses demonstrated a 
clear study result, namely high variability regarding anno-
tations for pathogenicity and actionability, which were 
similar to the comparisons of other platforms.12 13 Our study 
provides important novel aspects, including a comparison 
of the tools from an end user perspective. Furthermore, 
this study describes to the best of our knowledge for the 
first time not only in- depth comparisons of actionability, 
but also treatment recommendations. We demonstrate the 
complexity of treatment matching algorithms, which influ-
ences crucial discussions at MTBs and are thus pertinent to 
both oncologist and patient. Our results emphasise that the 
final treatment decision remains to be made at the discre-
tion of the treating clinician and, although decision support 
may accelerate interpretation of rare or complex genomic 
aberrations, the element of human interpretation cannot be 
replaced. Importantly, it has also been acknowledged that 
even national and international consensus in regard to treat-
ment recommendations resulting from MTBs is lacking, 
and some have begun to critically evaluate the effectiveness 
of the complex MTB decision- making methodology as well 
as adherence to the recommendation.27
Regarding NAVIFY and QCI, discrepancies may be 
attributed to the inherent variation in the AMP or mixed 
ACMG/AMP guidelines for determining actionability as 
Figure 5 Clinical trials identified per decision support platform. (A) Total number of matching clinical trials per tumour entity 
for NAVIFY (left), QCI (centre) and CureMatch (right). (B) Boxplot showing distribution of the highest and lowest calculated 
matching scores per patient across tumour types from CureMatch analysis. BC, breast cancer; CRC, colorectal cancer; 
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well as the main content sources used by each software 
to query therapies, ultimately leading to discrepant treat-
ment matching. For example, QCI considers FDA (Food 
and Drug Administration), EMA (European Medicines 
Agency) and Pharmaceuticals and Medical Devices Agency 
drug labels and oncology practice guidelines such as 
American Society of Clinical Oncology, NCCN (National 
Comprehensive Cancer Network), ESMO (European 
Society for Medical Oncology), Clinical Pharmacoge-
netics Implementation Consortium, College of American 
Pathologists, WHO and European LeukemiaNet. NAVIFY 
similarly queries approved therapies across multiple regu-
latory agencies, such as FDA, EMA, Swissmedic, National 
Institute for Health and Care Excellence, Health Canada, 
NCCN, ESMO and eviQ (eviQ Cancer Treatments 
Online), thus partially varying from the QCI content. 
It is worth noting that there are further discrepancies 
related to regional- specific content. In our analyses, we 
obtained content for the European Union clinical region, 
whereas those performing analyses based in the US clin-
ical region may obtain different results. Furthermore, 
curated content is constantly updated as new evidence is 
accumulated such that discrepancies found at the time of 
this study may no longer be relevant if the designations 
between platforms newly align for a particular variant, 
for example the approval of encorafenib in combina-
tion with cetuximab for the treatment of adult patients 
with BRAF V600E- mutant metastatic CRC (FDA approval 
April 2020; EMA approval June 2020). Additionally, the 
different algorithms of the platforms are also reflected by 
the fact that CureMatch and QCI analyses frequently clas-
sified TP53, KRAS and APC alterations, typically seen as 
non- actionable in standard practice, as druggable targets. 
However, it should be noted that QCI analyses matched 
various chemotherapy, anti- EGFR (epidermal growth 
factor receptor) and anti- VEGF (vascular endothelial 
growth factor) agents to the abovementioned alterations, 
thus not representing targeted therapies, which certainly 
does not fit into the current paradigm of what is under-
stood to constitute precision oncology. Conversely, the 
CureMatch strategy does not suggest experimental agents 
to directly act on these ‘undruggable targets’,28 29 but is 
rather a pathway- based method of targeting downstream 
events of the untargetable pathogenic alteration, an 
approach which some have tested previously.30–32 This 
highlights one major bottleneck of the precision oncology 
pipeline, as the varying strategies of tier classification and 
actionability are important to consider when designing 
large studies.
The very minimal alignment found when comparing 
platform outputs illustrates the complexity behind 
matching druggable targets to existing therapies, not 
to mention the pharmaceutical policies that vary from 
country to country and thus further influence treatment 
choices. Perhaps most surprising was that even for well- 
established druggable targets, such as ERBB2 amplifica-
tions or PIK3CA mutations, the platforms differed in their 
recommendations.
Our retrospective study has limitations. First, we did not 
test the informative value of the decision platforms in cases 
with very low ctDNA AFs, which is frequently an issue in 
patients with cancer,14 but rather used samples with rela-
tively high ctDNA AFs and thus a higher number of alter-
ations, which facilitated our platform comparison. Second, 
it was not an aim of our study to address the optimal time 
point for performing molecular profiling. Third, realising 
actionable results remains dependent on a list of other 
factors, for example access to drugs and long approval 
processes for off- label indications,1 particularly for tissue- 
agnostic marker- based indications, which are gaining more 
traction in precision oncology clinical trials.33 Finally, our 
analyses solely focused on the current status of the patient, 
meaning that prior lines of therapy, comorbidities and 
clinical status were not taken into account when it came to 
assigning treatments, as this was outside the scope of our 
study. Roche has since released an additional tool in the 
NAVIFY product portfolio, the NAVIFY Tumor Board. With 
this feature, outputs from the NAVIFY Mutation Profiler 
can be imported into the Tumor Board alongside other 
pertinent clinical details of the patient, for example, age, 
comorbidities, previous therapies, and so on, to assist 
clinicians at their MTB discussions. As the NAVIFY Tumor 
Board was not yet available at the time when we conducted 
our analyses, we were unable to subsequently evaluate how 
this would influence the matching of treatments to the 
molecular profiles we generated, although a prospective 
study is now being planned to address this question.
The high variability of the three platforms investigated 
by our group was obvious at each level of assessment, that 
is, pathogenicity, actionability and treatment recommenda-
tions, observations which are in line with recently published 
comparisons of other platforms.12 13 However, our study is 
the first, to the best of our knowledge, which also included 
detailed treatment recommendations and the alignment 
of drugs between platforms. Hence, our results illustrate 
the need for further development and testing of decision 
support algorithms.34 To this end, the abovementioned 
study, which compared six somatic cancer variant knowledge 
bases, harmonised variant interpretations from these data-
bases and made them available via a freely accessible web 
interface ( search. cancervariants. org).13 Other tools, such as 
Variant Interpretation for Cancer, which acknowledges that 
it should be employed alongside human reviewers, as well 
as the NIH- funded Clinical Genome Resource (ClinGen) 
effort Minimal Variant Level Data framework,35 36 have also 
contributed to minimising bias in the interpretation work-
flow. Our incomplete knowledge about how to optimally 
identify druggable targets and the lacking consensus in the 
processes delegating drug matching may be overcome by 
such cooperative and global efforts, in turn contributing to 
the realisation of the promising precision oncology concept.
METHODS
Patient cohort
The study was approved by the Ethics Committee of 
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21-229 ex 09/10) and the University Medical Center 
Groningen (METc approval number METc 2017/217) 
and conducted according to the Declaration of Helsinki. 
Written informed consent was obtained from all patients. 
Patients with metastatic breast cancer (n=12) and CRC 
(n=17) were recruited and treated at the Department of 
Internal Medicine, Division of Oncology, at the Medical 
University of Graz and patients with stage IIIB and stage 
IV NSCLC (n=19) were recruited and treated at UCMG at 
the University of Groningen. General clinical characteris-
tics for each patient are outlined in online supplemental 
table S1 and figure S1.
Shallow whole-genome sequencing (plasma-Seq) for SCNA 
analysis
Plasma DNA was isolated using the QIAamp Circulating 
Nucleic Acid Kit (QIAGEN, Hilden, Germany) from 
2 mL of plasma and samples were quantified with the 
Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, 
Vienna, Austria). Whole- genome sequencing libraries were 
prepared as described previously in detail.20 Libraries were 
sequenced on either an Illumina MiSeq or NextSeq instru-
ment (Illumina, San Diego, California, USA) for the gener-
ation of 75 bp paired- end reads. SCNA data analysis and 
identification of significant tumour- specific focal events was 
performed as described previously37–39; focal amplifications 
can be reliable called down to an AF of 5%.21
Estimation of tumour fraction from shallow whole- 
genome sequencing data was performed using the 
ichorCNA algorithm, a probabilistic Hidden Markov Model 
model for the estimation of tumour fraction, roughly equiv-
alent to tumour purity from bulk tumour analyses.22
Mutation profile generation with AVENIO ctDNA expanded 
panel
Library preparation for mutation calling was performed 
using 10–50 ng of input DNA with the AVENIO ctDNA 
Expanded Kit (Roche) in accordance with the manufactur-
er’s instructions. This assay is specifically designed for the 
profiling of ctDNA to identify genomic aberrations derived 
from solid tumours. The panel consists of 77 genes covering 
a total of 192 kb, including those currently in the US NCCN 
guidelines as well as emerging biomarkers currently being 
investigated in clinical trials. A full list of genes and covered 
regions is shown in online supplemental table S2. The 
AVENIO platform was previously extensively validated in 
our lab using commercially available highly multiplexed 
reference standards with distinct mutations at defined 
allele frequencies, which enabled variant detection down to 
a variant allele frequency (VAF) of 0.125%.40
Libraries were sequenced 150 bp paired- end on an 
Illumina NextSeq, obtaining between 30 and 40 million 
paired- end reads per sample. Data analysis was performed 
using the AVENIO ctDNA Analysis Software (Roche) with 
customised somatic variant filtration settings. Briefly, vari-
ants commonly found in germline with an allele frequency 
≥1% as defined by 1000 Genomes or ExAC were removed 
along with common single nucleotide polymorphisms as 
defined by single nucleotide polymorphism databases. 
Intron variants except for novel splice site variants, likely 
germline variants, synonymous variants and copy number 
alterations (MET, ERBB2, EGFR) with copy number vari-
ation scores <5 were omitted from analysis. Variants were 
only kept if the mutant read depth was >10 reads and 
significant filtered somatic variants were summarised in 
a VCF file for subsequent input into the various clinical 
decision support platforms (NAVIFY, QCI). For Cure-
Match analysis, VCF files for each patient were annotated 
for pathogenicity and clinical relevance using publicly 
available databases and summarised in a PDF report for 
off- site analysis.
Statistical analyses
Correlation analyses were performed using a Pearson 
correlation. Statistical analysis was performed using the 
ggpubr package in R. A p value of <0.05 was considered 
to be statistically significant.
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